CT26-EphA2 tumor cells were treated in vitro with 1) the non-ICD-inducing agent cisplatin; 2) the ICD-inducing agent doxorubicin and 3) ICD-inducing photoimmunotherapy. This evidence concerns the gene EPHA2 and neoplasm.